Andropause (or symptomatic late-onset hypogonadism): Facts, fiction and controversies

Aging Male

Volumn 7, Issue 4, 2004, Pages 297-303

  Morales, A ^a,b  

^a QUEEN S UNIVERSITY   (Canada)

^b Department of Urology ^*  (Canada)

Author keywords

Andropause; Prostate cancer; Symptomatic late onset hypogonadism; Testosterone; Testosterone therapy

Indexed keywords

ANDROGEN; ANDROGEN RECEPTOR; ANDROSTANOLONE; EPITESTOSTERONE; ESTROGEN; GROWTH HORMONE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; MELATONIN; NEURONAL NITRIC OXIDE SYNTHASE; NON PRESCRIPTION DRUG; PHOSPHODIESTERASE V; PHOSPHODIESTERASE V INHIBITOR; PLACEBO; PRASTERONE; PROGESTERONE; PROSTATE SPECIFIC ANTIGEN; SEX HORMONE; SEX HORMONE BINDING GLOBULIN; SILDENAFIL; TESTOSTERONE; THYROXINE; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGING; ANDROGEN DEFICIENCY; ANDROGEN DEFICIENCY OF THE AGING MALE; ANDROGEN THERAPY; ANDROPAUSE; BLOOD TOXICITY; BREAST CANCER; CARDIOVASCULAR DISEASE; CLINICAL FEATURE; CLINICAL TRIAL; CONFERENCE PAPER; DIFFERENTIAL DIAGNOSIS; DRUG EFFICACY; DRUG SAFETY; ERECTILE DYSFUNCTION; ESTROGEN THERAPY; FLUID RETENTION; FOLLOW UP; GONAD FUNCTION; GYNECOMASTIA; HORMONE ACTION; HORMONE BLOOD LEVEL; HORMONE SUBSTITUTION; HUMAN; HYPOGONADISM; LIVER TOXICITY; MOOD DISORDER; NOMENCLATURE; PATIENT MONITORING; POSTMENOPAUSE; PRESCRIPTION; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE HYPERTROPHY; RISK BENEFIT ANALYSIS; SEXUAL FUNCTION; SIDE EFFECT; SLEEP DISORDER; SYMPTOM; SYMPTOMATIC LATE ONSET HYPOGONADISM; TESTOSTERONE BLOOD LEVEL; TESTOSTERONE SYNTHESIS;

AGING; ANDROPAUSE; HUMANS; HYPOGONADISM; MALE; TESTOSTERONE;

EID: 11244309799     PISSN: 13685538     EISSN: None     Source Type: Journal    
DOI: 10.1080/13685530400016664     Document Type: Conference Paper

References (19)

1. Wagner AA. The male climacteric: report of two hundred and seventy three cases. J Am Med Assoc 1946;132:188-94
2. Morales A, Heaton JP, Carson CC 3rd. Andropause: a misnomer for a true clinical entity. J Urol 2000;163:705-12
3. Writing Group for the Women's Health Initiative. Risks and benefits of estrogens and progestins in healthy post-menopausal women. J Am Med Assoc 2002;288:321-33
4. Muller M, van der Schouw YT, Thijssen JH, Grobbee DE. Endogenous sex hormones and cardiovascular disease in men. J Clin Endocrinol Metab 2003;88:5076-86
5. Bhasin S, Singh AB, Mac RP, Carter B, Lee MI, Cunningham GR. Managing the risks of prostate disease during testosterone replacement therapy in older men: recommendations for a standardized monitoring plan. J Androl 2003;24:299-311
6. Liverman CT, Blazer DG, eds. Institute of Medicine of the National Academies. Testosterone and aging. Committee on assessing the need for clinical trials of testosterone replacement therapy. Washington DC, USA: The National Academies Press, 2004
7. Vermeulen A, Verdonck L, Kaufman JM. A critical evaluation of simple methods for the estimation of free testosterone in serum. J Clin Endocrinol Metab 1999;84:366-71
8. Morley JE, Patrick P, Perry HM 3rd. Evaluations of assays available to measure free testosterone. Metabolism 2002;51:554-9
9. Hepatic effects of 17 alpha-alkylated anabolic-androgenic steroids. HIV Hotline. 1998;8:2-5
10. Jin B, Conway AJ, Handelsman AJ. Effects of androgen deficiency and replacement on prostate zonal volumes. Clin Endocrinol (Oxf) 2001;54:437-45
11. Zitzmann M, Depenbusch M, Gromoll J, Nieschlag E. Prostate volume and growth in testosterone-substituted hypogonadal men are dependent on the CAG repeat polymorphism of the androgen receptor gene: a longitudinal pharmacogenetic study. J Clin Endocrinol Metab 2003;88:2049-54
12. Morales A. Androgen replacement therapy and prostate safety. Eur Urol 2002;41:113-20
13. English KM, Mandour O, Steeds RP, Diver MJ, Jones TH, Channer KS. Men with coronary artery disease have lower levels of androgens than men with normal coronary angiograms. Eur Heart J 2000;21:890-4
14. Alexandersen P, Haarbo J, Christiansen C. The relationship of natural androgens to coronary heart disease in males: a review. Atherosclerosis 1996;125:1-13
15. Hak AE, Witteman JC, de Jong FH, Geerlings MI, Hofman A, Pols HA. Low levels of endogenous androgens increase the risk of atherosclerosis in elderly men: the Rotterdam Study. J Clin Endocrinol Metab 2002;87:3632-9
16. Carani C, Bancroft J, Granata A, Del Rio G, Marrama P. Testosterone and erectile function, nocturnal penile tumescence and rigidity, and erectile response to visual erotic stimuli in hypogonadal and eugonadal men. Psychoneuroendocrinology 1992;17:647-54
17. Traish AM, Park K, Dhir V, Kim NN, Moreland RB, Goldstein I. Effects of castration and androgen replacement on erectile function in a rabbit model. Endocrinology 1999;140:1861-8
18. Aversa A, Isidori AM, Spera G, Lenzi A, Fabbri A. Androgens improve cavernous vasodilation and response to sildenafil in patients with erectile dysfunction. Clin Endocrinol (Oxf) 2003;58:632-8
19. Benito M, Gomberg B, Wehrli FW, et al. Deterioration of trabecular architecture in hypogonadal men. J Clin Endocrinol Metab 2003;88:1497-502